Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update

Published on: Monday 28 February 2022

As of February 2022, more than 100 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy Clinical data updates planned for lead program Zeno in 1H22 and for petosemtamab (“MCLA-158”) and MCLA-129 in 2H22 Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations beyond 2024 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Me

News source: https://finance.yahoo.com/news/merus-announces-financial-results-fourth-213700500.html

Share this news on: Facebook Twitter

» The new government has plans to get the housing market moving

» King’s Day was ‘old-fashioned fun’, royals celebrate in Maastricht

» Scientists Call for Ultimate Producer Responsibility

» Netherlands suffering of over-tourism: time for destination management instead of destination promotion

HEADLINE NEWS

My Financial News from Utrecht, Netherlands

Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update